Sustained response with gemcitabine plus Nab-paclitaxel after folfirinox failure in metastatic pancreatic cancer: Report of an effective new strategy - 23/04/14

Doi : 10.1016/j.clinre.2014.01.005

Alix Portal ^a, Simon Pernot ^a, Nathalie Siauve ^b, Bruno Landi ^a, Céline Lepère ^a, Orianne Colussi ^a, Philippe Rougier ^a, Aziz Zaanan ^a, Benjamin Verrière ^c, Julien Taieb ^a,^⁎
^a Service d’hépatogastro-entérologie et d’oncologie digestive, université Paris Descartes, Sorbonne Paris-Cité, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France
^b Service de radiologie, université Paris Descartes, Sorbonne Paris-Cité, hôpital européen Georges-Pompidou, Paris, France
^c Service de pharmacie, université Paris Descartes, Sorbonne Paris-Cité, hôpital européen Georges-Pompidou, Paris, France

^⁎Corresponding author. Tel.: +33 1 56 09 50 42; fax: +33 1 53 98 79 52.

Summary

Introduction

Folfirinox has shown a benefit in terms of survival and quality of life in first line treatment of metastatic pancreatic cancer. However, efficacy of second line chemotherapy after folfirinox is still limited. Gemcitabine plus Nab-paclitaxel have been recently validated as first line treatment with an increased overall survival compared to gemcitabine. This combination has never been studied as second-line after folfirinox.

Case report

A metastatic pancreatic cancer was diagnosed in a 60-year-old patient with a performance status of 0. After 10 cycles of folfirinox, and an initial objective response, we objectively noted progressive disease according to the RECIST 1.1 criteria together with an increased carbohydrate antigen 19-9. The multidisciplinary team decided to use gemcitabine plus Nab-paclitaxel as second line palliative chemotherapy. After 2 months, we obtained an objective response. After 6 months, this response was maintained with an acceptable tolerability.

Conclusion

Gemcitabine plus Nab-paclitaxel, as second line palliative chemotherapy, after failure of folfirinox, could be a good strategy for patients with a performance status of 0 and 1. Obviously, this data has to be confirmed in larger patients series and in future comparative clinical studies.

Le texte complet de cet article est disponible en PDF.

Plan

Introduction

Patient case presentation

Discussion

Conclusion

Disclosure of interest

Export

Vol 38 - N° 2

P. e23-e26 - avril 2014 Retour au numéro

Article précédent

The changes in MUC5AC expression in gastric cancer before and after Helicobacter pylori eradication
Ding Shi, Xin-min Qiu, Xing-jun Yan

| Article suivant

Stump appendicitis. A diagnostic trap
Renato M. Lupinacci, Cécile Bouchet-Doumenq, Harika Salepcioglu, Sophie Egels, Fabrice Menegaux, Christophe Trésallet

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

connectez-vous ou créez un compte

Sustained response with gemcitabine plus Nab-paclitaxel after folfirinox failure in metastatic pancreatic cancer: Report of an effective new strategy - 23/04/14

Summary

Introduction

Case report

Conclusion

Plan

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL